Loading
PA
PAR Stock: price and insider trades · Australia
PAR: what insiders have been doing
This page follows insider dealings at PAR as filed with ASX, a company from the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 2 filings came from 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (2,530 companies, median 3 filings), a count of 2 filings is below the norm.
There has been no open-market purchase by an insider of PAR for at least a year.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.25
Analyst consensus
2 analysts1.00/5
A$0.42Target A$1.08(+341%)A$1.74
Income statement
RevenueA$80.2k
Gross profitA$68k85% margin
EBITDA-A$53.7M-67024% margin
Net income-A$56.3M-70282.3% margin
Valuation
PER (forward)1.3x
P/Book40.8x
Beta0.02
Balance sheet & cash
Market capA$153.5M
Total debtA$7.5M
Free Cash Flow-A$44.2M
Debt / Equity216%
Profitability & ownership
ROE-457.0%
ROA-138.8%
% insiders9.6%
% institutions4.6%
Last declaration on 1 July 2026
About PAR
PAR is a company operating in the healthcare and pharmaceutical sector, listed on the XASX. It focuses on the development and commercialization of innovative solutions for patient well-being.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
